Short telomeres increase the risk of severe COVID-19.
Level 4 - case-series / case-control
Case-control comparison and prospective observational cohort with reference controls
PubMed 33104521 · doi:10.18632/aging.104097
What was done
In a prospective study, leukocyte telomere length (TL) was measured by Flow-FISH in 70 hospitalized COVID-19 patients and compared to a reference cohort of 491 healthy volunteers. Researchers correlated TL with baseline laboratory parameters (C-reactive protein and neutrophil-to-lymphocyte ratio) and clinical outcomes (critical disease defined as ICU admission or death without ICU). Senescence-associated beta-galactosidase activity was evaluated in autopsy lung tissue from six deceased COVID-19 patients.
What was found
COVID-19 patients had a significantly higher proportion of short telomeres (<10th percentile) than the reference cohort (P < 0.001). Short telomeres were associated with a higher risk of critical disease and were negatively correlated with C-reactive protein and neutrophil-to-lymphocyte ratio. Lung tissue from non-survivors with very short telomeres showed signs of cellular senescence in structural and immune cells. Specific numerical effect sizes, odds ratios, and correlation coefficients were not reported in the abstract.
Why it matters
Telomere length and biological aging may help explain why individuals of the same chronological age experience widely divergent clinical severity and mortality when infected with SARS-CoV-2.
Limits
The COVID-19 patient sample was small (n = 70 total, n = 6 autopsy cases), and the abstract provides no numerical effect estimates, odds ratios, or confidence intervals. The observational design cannot prove causality between short telomeres and adverse clinical outcomes or rule out residual confounding by underlying health status.
Cited by
- partial In COVID-19, immune senescence characterized by short telomeres in T lymphocytes was a lethal factor.